- Truist Securities BioPharma Symposium
November 9, 2023
Jefferies London Healthcare Conference November 15, 2023 , corporate presentation at12:30 pm GMT - 6th Annual
Evercore ISI HealthCONx Conference November 30, 2023 , fireside chat at10:00 am EST
For more information and links to available webcasts, visit the Events page on Caribou’s website. Webcasts will be available on the Caribou website for 30 days after the events.
About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About
Investors:
investor.relations@cariboubio.com
Media:
media@cariboubio.com
Source:
2023 GlobeNewswire, Inc., source